Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1281-1300 of 2,251 trials

Locally Recurrent Rectal Cancer: Induction Chemotherapy Study

We are comparing the effects of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone for patients with locally recurrent rectal cancer. This study aims to see which approach leads to better surgical outcomes and survival rates.

Recurrent Rectal CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Bladder Cancer: ONCOFID-P-B Treatment Study

We are studying a new treatment called ONCOFID-P-B for patients with Carcinoma in Situ of the bladder who have not responded to standard care. The goal is to see if this treatment can effectively reduce tumors and improve patient outcomes.

Bladder Cancer in Situ1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Muscle-Invasive Bladder Cancer: Erdafitinib Treatment Study

We are studying the effects of erdafitinib alone and with cetrelimab in patients with muscle-invasive bladder cancer who cannot take cisplatin. The goal is to see if this treatment can shrink tumors before surgery.

Muscle-Invasive Bladder Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Gene Therapy for Hearing Loss: AAVAnc80-hOTOF

We are studying a new gene therapy for people with hearing loss due to Otoferlin gene mutations. The trial aims to assess the long-term safety and effectiveness of this treatment.

Otoferlin Gene-Mediated Hearing Loss>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNeurologyOtolaryngology

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Diabetic Foot Ulcers: Comparing Two Treatments

We are studying whether Hypochlorous Acid or Polyhexamethylene biguanide helps heal diabetic foot ulcers more effectively. This trial will also look at healing size, depth, and quality of life for participants.

Diabetic Foot Ulcer3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteDiabetologyInfectious DiseasesInternal Medicine

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Endometrial Stromal Sarcoma: Aromatase Inhibitor Treatment Study

We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.

Low-Grade Endometrial Stroma Sarcoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Gastrointestinal Stromal Tumors: Imatinib Treatment Study

We are exploring whether continuing or stopping imatinib treatment after 10 years benefits patients with advanced GISTs. The study looks at health outcomes like survival rates and quality of life.

Locally Advanced or Metastatic Gastrointestinal Stromal Tumors>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

X-Linked Hypohidrotic Ectodermal Dysplasia: ER004 Treatment

We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.

X-linked Hypohidrotic Ectodermal Dysplasia≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicinePediatrics

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Protecting Children from Radiation-Induced Hypothyroidism

We are studying whether TSH suppression during radiation therapy can lower the risk of hypothyroidism in children with medulloblastoma and lymphomas. This trial also examines any changes in thyroid tissue after treatment.

Hodgkin and Non-Hodgkin LymphomaMedulloblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Thyroid Eye Disease: Batoclimab Extension Study

We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.

Thyroid Eye Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia

We are studying different conditioning treatments for children and adolescents with acute lymphoblastic leukemia undergoing stem cell transplantation. Our goal is to find out which treatment leads to better survival and fewer side effects.

Acute Lymphoblastic Leukaemia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Cardio Renal Syndrome: Peritoneal Ultrafiltration Treatment

We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.

Congestive Heart Failure>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrology

Wiskott-Aldrich Syndrome: Gene Therapy Follow-Up

We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.

Wiskott-Aldrich Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematology

Bladder Cancer: Neoadjuvant Chemotherapy Study

We are testing whether bladder instillation of neoadjuvant chemotherapy can help prevent recurrence in patients with non-muscle-invasive bladder cancer. This study compares it to standard treatment to assess effectiveness and side effects.

Non-muscle invasive bladder cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology